> ## Content Index > Fetch the complete content index at: https://compoundcodex.org/llms.txt > Use this file to discover other available public pages before exploring further. # BPC-157 for tendon and soft-tissue healing - URL: https://compoundcodex.org/bpc-157/ - Published: 2026-08-22T06:35:05.000Z - Updated: 2026-08-24T08:07:24.000Z - Description: Does BPC-157 accelerate healing of tendons, ligaments, or gut tissue in humans? - Author: The Archivist - Tags: peptides, grade-preliminary, verdict-untested, bpc-157 Preliminary evidence Untested in humans ⚑ Not characterised Marks reviewed Aug 2026 5 sources cited Next review Aug 2027 --- ## Why this one is different Most compounds we cover are swallowed. This one is injected, by a large number of people, on the strength of an evidence base that does not include a single completed randomized controlled trial in humans. BPC-157 is a synthetic fifteen-amino-acid peptide, described as a fragment derived from a protein found in human gastric juice. In rodents it has been reported to accelerate healing across an unusually wide range of tissues — tendon, muscle, bone, gut lining, even nerve. The animal literature is genuinely substantial and genuinely interesting. None of that is the same as knowing what it does in a person. ## The human evidence, in full This section is short because it can be. Here is the complete set of human trial evidence we could locate. #### Every human trial we could identify NCT02637284 — Phase I safety and pharmacokinetics Sponsored by PharmaCotherapia d.o.o. Registered for 42 healthy volunteers. Listed start October 2015, estimated completion March 2016. Status "unknown" · no results posted[2](#c2) PLIVA trials — BPC-157 enemas for ulcerative colitis, 2000s Two relatively small company trials. Reporting by Undark found the resulting papers do not appear in major databases such as PubMed, and it is unclear whether they were ever published in a peer-reviewed journal. Not independently verifiable[5](#c5) Completed randomized controlled trials with published results 0 The Phase I trial is the striking one. It was registered a decade ago with an estimated completion date of March 2016\. As of this review its status remains "unknown," and the registry records no posted results.[2](#c2) Undark's investigation reports that data was submitted and then withdrawn before outside review.[5](#c5) A trial that finishes and reports is evidence. A trial that finishes and doesn't report is not neutral — it is a missing data point, and missing data points are not distributed randomly. ## The problem with counting the animal studies Search PubMed and you will find roughly 200 BPC-157 papers. That number is the single most cited fact in favour of the compound, and it is the most misleading. Undark's investigation found that the vast majority of those studies include either Predrag Sikiric or his colleague Sven Seiwerth as a main author — nearly all the existing data traces to one research group at the University of Zagreb.[5](#c5) Under our definition, an **independent group** shares no senior authors, no institution, and no funding source with the other trials being counted. Applying that definition, a literature of roughly 200 studies collapses to approximately **one** independent group. Replication is what converts a finding into knowledge. Two hundred papers from one lab is not two hundred replications — it is one laboratory's programme of research, repeated. Undark further reports that Sikiric is named on BPC-157 patent applications dating back to at least 1989, appears in Croatian government records as an owner of PharmaCotherapia — the company that sponsored the registered human trial — and is CEO of Diagen, which says it holds a patent on a stabilised version of the peptide. According to that reporting, these interests were not disclosed on any of the team's published papers Undark reviewed.[5](#c5) None of this means the animal findings are wrong. Undisclosed conflicts do not falsify a result. What they do is remove the independent check that would let a reader distinguish a real effect from a motivated one — which is precisely the check that replication by unaffiliated groups is supposed to provide. ## Where regulators have landed Three separate authorities have assessed BPC-157, and none of them concluded it is dangerous. They concluded something more specific: nobody knows. The FDA evaluated BPC-157 as a bulk drug substance nominated for use in pharmacy compounding and placed it in category 2 — substances that may present significant safety risks. It now appears on the agency's list of category 2 nominations subsequently withdrawn by the nominator, with the original assessment published: > Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. US Food and Drug Administration[1](#c1) The World Anti-Doping Agency prohibits BPC-157 under class S0, non-approved substances — banned at all times, in and out of competition, with no therapeutic use exemption available. USADA notes it is not approved for human clinical use by the FDA or any other global health authority, and states plainly that because it has not been extensively studied in humans, it is unknown whether there is a safe dose or any safe way to use it.[3](#c3) The US Department of Defense lists it as a prohibited ingredient under directive 6130.06, describing it as an unapproved drug that is not a dietary ingredient and cannot legally be prescribed or sold over the counter.[4](#c4) ## Safety and unknowns - Adverse events reported No published human trial data exists from which to report adverse event rates. This is an absence of information, not a finding of safety. - Longest human exposure studied Unknown. The only registered Phase I trial has never posted results.[2](#c2) No published trial establishes a duration of characterised human exposure. - Known interactions and at-risk groups Not characterised. FDA specifically flags immunogenicity risk for certain routes of administration, and complexities with peptide-related impurities and active-ingredient characterisation.[1](#c1) - Regulatory status Not approved by the FDA or EMA for any indication. Prohibited by WADA under class S0 at all times, no TUE available.[3](#c3) On the DoD prohibited ingredients list.[4](#c4) Not a dietary ingredient; commonly sold labelled "research use only" or "not for human consumption."[4](#c4) - What has not been characterized In humans: efficacy, safety, pharmacokinetics, dose-response, drug interactions, and long-term effects — all of it. Separately, product identity and purity are uncharacterised: material sold as a research chemical is not manufactured to pharmaceutical quality standards, and no trial cited here speaks to what is actually in any given vial. **The standing rule, applied:** the safety profile of BPC-157 in humans *has not been characterized*. That is not the same sentence as "no side effects have been reported," and the difference matters more here than anywhere else on this site. Absence of reported harm in rodents is not evidence of human safety. If you are considering this compound, that conversation belongs with a clinician who knows your history. ## How this was graded #### Evidence strength — Preliminary, criteria checked Completed qualifying trials in humans0 ✗ Registered trials with posted results0 ✗ Independent groups in the animal literature\~1 ✗ Published systematic review of human trialsnone possible ✗ Animal and mechanistic worksubstantial ✓ With zero completed qualifying trials, the verdict axis reads **Untested in humans** rather than supported or refuted. We are not saying BPC-157 doesn't work. We are saying the study that would tell you has not been published — and that one dot is what an unanswered question looks like on this scale. ## What would change this grade Unusually for this site, the path is precise and short. One completed, published, placebo-controlled human trial in a defined indication would move BPC-157 from Preliminary to Emerging immediately, whatever it found. Posted results from NCT02637284 alone would materially change what can be said about human safety. Replication of the core animal findings by a group with no ties to Zagreb and no financial interest would strengthen the preclinical case that currently rests on a single laboratory. Until one of those things happens, the honest position is not scepticism about the mechanism. It is that the question remains open, and that a great many people are currently answering it on themselves. ## Bottom line There is no published randomized controlled trial showing that BPC-157 does anything in a human being. The single registered Phase I safety trial was due to complete in 2016 and has never reported. The animal literature is real but is not the two hundred independent replications the raw paper count implies — nearly all of it traces to one laboratory whose lead researcher holds patents and company interests that reporting found were undisclosed in the published work. Regulators have not called it dangerous; they have said they lack the information to know. That is the accurate summary, and it is the reason this page carries one dot. peptides grade-preliminary verdict-untested bpc-157 ## Sources 1. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the FD&C Act. BPC-157 listed under nominations subsequently withdrawn. Content current as of 22 April 2026\. [fda.gov](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?ref=compoundcodex.org) 2. ClinicalTrials.gov. NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157. Sponsor: PharmaCotherapia d.o.o. Enrollment 42 (estimated). Status: unknown. Results posted: no. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02637284?ref=compoundcodex.org) 3. US Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes. [usada.org](https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/?ref=compoundcodex.org) 4. US Department of Defense, Operation Supplement Safety. BPC-157: A Prohibited Peptide and an Unapproved Drug Found in Health and Wellness Products. [opss.org](https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products?ref=compoundcodex.org) 5. Undark. BPC-157: A MAHA-Adjacent Peptide, Linked to Croatia. 3 February 2026\. [undark.org](https://undark.org/2026/02/03/bpc-157-peptide-fda/?ref=compoundcodex.org) — investigative reporting, cited for authorship concentration, undisclosed financial interests, and the status of the PLIVA trials. Search results for this compound are dominated by vendor and supplement-marketing pages. Under our sourcing standard none of those are usable as evidence for any mark, and none were used here. **The Compound Codex** — every mark on this page is assigned under our [public editorial standards](https://compoundcodex.org/editorial-standards/). The rubric is versioned, its revisions are logged, and any grade here is open to challenge. This breakdown summarizes published research and regulatory records for informational purposes only. It is not medical advice and does not endorse the use of any compound discussed. No dose or protocol for human use is described anywhere on this page. Always consult a qualified clinician before considering any peptide, and be aware that BPC-157 is an unapproved drug prohibited in sport and on the US Department of Defense prohibited ingredients list. © 2026 The Compound Codex · Every claim cited, none of them prescriptive.